Latest News & Updates

Breaking News

  • 2 hours ago

  • Simantini Singh Deo

Teva And Royalty Pharma Announce $500M Collaboration To Advance TEV-‘408 For Vitiligo After Promising Early Data; Further Readouts In 2026
Breaking News
Benitec Reports Durable 24-Month BB-301 Benefits In Phase 1b/2a OPMD Dysphagia Study

Vaibhavi M.

Other trending news you may like to read

Teva And Royalty Pharma Announce $500M Collaboration To Advance TEV-‘408 For Vitiligo After Promising Early Data; Further Readouts In 2026

Royalty Pharma backs Teva with up to $500M to accelerate clinical development of the anti-IL-15 antibody TEV-408.

Simantini Singh Deo

Pharma Now

Benitec Reports Durable 24-Month BB-301 Benefits In Phase 1b/2a OPMD Dysphagia Study

Benitec reports durable 24-month clinical improvements with BB-301 in a rare muscle disorder affecting swallowing.

Vaibhavi M.

Pharma Now

Pharmapack 2026 to Return to Paris with Focus on GLP-1 Innovation and Sustainable Packaging

Pharmapack 2026 brings global pharma packaging leaders to Paris, spotlighting GLP-1 delivery, sustainability, and innovation.

Team Pharma Now

Pharma Now

CorMedix CEO Joseph Todisco Extends Contract, Becomes Chairman Of The Board As Myron Kaplan Transitions to Lead Independent Director; Mike Seckler Joins As EVP & Chief Commercial Officer

CorMedix strengthens leadership with Joseph Todisco becoming Chairman and Mike Seckler joining as Chief Commercial Officer.

Simantini Singh Deo

Pharma Now